



## MODIGENE TO PRESENT AT UBS 2007 GLOBAL LIFE SCIENCES CONFERENCE

**VIENNA, VA September 18, 2007** -- Modigene Inc. (OTCBB: MODG) today announced that senior management will present at the UBS 2007 Global Life Sciences Conference on Wednesday, September 26, 2007 at 12:00 pm EDT. The conference will be held at the Grand Hyatt New York in New York City.

Modigene CEO Abraham Havron and President Shai Novik will attend. Management will provide a company overview and review of corporate developments.

The audio portion of the company's presentation will be webcast live. It can be accessed at the Investors section of the Modigene website at [www.modigeneinc.com](http://www.modigeneinc.com). An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation. The live and archived audio webcast can also be accessed at the UBS website at <http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924>

For more information about the UBS 2007 Global Life Sciences Conference, visit [www.presentationsmedia.com/globallifesciencesev/about.html](http://www.presentationsmedia.com/globallifesciencesev/about.html).

### ABOUT MODIGENE

Modigene Inc. (OTCBB: MODG) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit [www.modigeneinc.com](http://www.modigeneinc.com).

***Safe Harbor Statement:** This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.*

MODIGENE CONTACT:  
Shai Novik, President  
Modigene Inc.  
Tel: +1 866 644-7811  
Email: [shai@modigeneinc.com](mailto:shai@modigeneinc.com)

MEDIA CONTACT:  
Barbara Lindheim  
GendeLLindheim BioCom Partners  
+1 212 918-4650